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Even though there is extensive research carried out in radiation oncology, most of the 
clinical studies focus on the effects of radiation on the local tumor tissue and deal with 
normal tissue side effects. The influence of dose fractionation and timing particularly 
with regard to immune activation is not satisfactorily investigated so far. This review, 
therefore, summarizes current knowledge on concepts of modern radiotherapy (RT) and 
evaluates the potential of RT for immune activation. Focus is set on radiation-induced 
forms of tumor cell death and consecutively the immunogenicity of the tumor cells. The 
so-called non-targeted, abscopal effects can contribute to anti-tumor responses in a 
specific and systemic manner and possess the ability to target relapsing tumor cells 
as well as metastases. The impact of distinct RT concepts on immune activation is 
outlined and pre-clinical evidence and clinical observations on RT-induced immunity 
will be discussed. Knowledge on the radiosensitivity of immune cells as well as clinical 
evidence for enhanced immunity after RT will be considered. While stereotactic ablative 
body radiotherapy seem to have a beneficial outcome over classical RT fractionation in 
pre-clinical animal models, in vitro model systems suggest an advantage for classical 
fractionated RT for immune activation. Furthermore, the optimal approach may differ 
based on the tumor site and/or genetic signature. These facts highlight that clinical trials 
are urgently needed to identify whether high-dose RT is superior to induce anti-tumor 
immune responses compared to classical fractionated RT and in particular how the 
outcome is when RT is combined with immunotherapy in selected tumor entities.
Keywords: radiotherapy, norm- and hypofractionation, SABR, abscopal effect, anti-tumor immunity
The primary goal of radiotherapy (RT) in cancer therapy is to eliminate the disease by restricting 
the reproductive potential of tumor cells. This is achieved by the induction of tumor cell death 
as well as the inhibition of the proliferating capacity of the cells (1). RT is a valuable therapy that 
is able to control tumor growth, eliminate the tumor, reduce the risk of cancer recurrence, and 
ultimately to improve survival (2). Radiation predominantly induces DNA damage in the cells (3) 
and some of its most prominent consequences are apoptosis, necrosis, mitotic catastrophe (MC), 
autophagy, cell cycle arrest, and/or senescence (Figure 1). About 60% of patients with solid tumors 
receive RT [15% RT monotherapy, 45% radiochemotherapy (RCT)], making it the most common 
treatment option for cancer (4, 5). Recent advances in radiation technologies have opened the 
field for new and promising radiation strategies, such as the stereotactic ablative body radio-
therapy (SABR). However, while it has become generally accepted that RT is capable of inducing 
FiGURe 1 | Primary and secondary effects of radiation. The primary target of radiation within the tumor cells is the DNA. It aims to eliminate the tumor through 
inhibition of its proliferating capacity and by induction of cell death. Necrosis, apoptosis, mitotic catastrophe (MC), autophagy, and senescence might occur after 
radiation-induced DNA-damage. However, radiotherapy (RT) also has a secondary, non-targeted effect that is achieved through a modification of the tumor 
phenotype, the tumor microenvironment, and/or the induction of an immunogenic cell death (ICD), characterized by the release of danger-associated molecular 
patterns (DAMPs) and cytokines (e.g., but not exclusively Hsp70, HMGB1, IL-6, IL-8; TNF-α). All of these contribute to the activation of immune-mediated local and 
distant reactions on the tumor and metastases.
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anti-tumor immunity (6), little is known about the effects of 
particular high-dose RT on the immune system. In this review, 
we will, therefore, deal with radiation-induced cell responses, 
current state-of-the-art radiation protocols, as well as the direct 
or indirect impact of fractionation schemes and radiation doses 
on the cells of the immune system, including limitations and 
draw-backs of today’s radiation research.
RADiATiON-iNDUCeD CeLL ReSPONSeS
The main purpose of RT is the induction of directly targeted 
effects, which are usually well understood and characterized. 
However, less is known about the so-called non-targeted effects 
that are often mediated by the immune system and originate from 
radiation-induced cell death forms.
Radiation-induced Apoptosis
Apoptosis is the best characterized form of programed cell death, 
which plays a major role during cell development, growth, and dif-
ferentiation, and is important to maintain a healthy homeostatic 
balance (7, 8). It is characterized by morphological hallmarks, 
such as cellular shrinkage, chromatin condensation, nuclear 
fragmentation, and membrane blebbing (9). Cells undergoing 
apoptosis are engulfed by phagocytes in an anti-inflammatory 
manner (10, 11). During cancer development, however, tumor 
cells acquire several resistance mechanisms against apoptosis, 
such as the expression of anti-apoptotic proteins, the inactivation 
of pro-apoptotic genes, modifications of the p53 pathway, and an 
altered survival signaling (12). Following ionizing radiation, an 
upregulation of various proteins of the death receptor pathway 
(p53-dependently and -independently) can be observed that 
might contribute to radiation-induced apoptosis (9). Although 
apoptosis does not seem to be the predominant form of cell death 
that is induced by RT in treatment of solid cancer, a positive cor-
relation between tumor response and the amount of spontaneous/
radiation-induced apoptosis can be found (13).
Radiation-induced Necrosis
Necrosis is often described as an uncontrolled form of cell death, 
which is morphologically characterized by the gain of volume, 
swelling of organelles, plasma membrane rupture, and loss of 
intracellular contents. However, there is emerging evidence that 
necrosis, such as apoptosis, can be regulated through a set of 
signal transduction pathways and catabolic mechanisms (14). As 
cells release damage-associated molecular patterns (DAMPS), 
such as heat shock proteins (HSP) or high mobility group box 1 
(HMGB1) when they undergo necrosis, it is widely considered as 
an pro-inflammatory and immune activating form of cell death 
(15, 16). After RT, necrosis often follows MC, finally resulting in 
local inflammation (3).
Radiation-induced Mitotic Catastrophe
Mitotic catastrophe is among the most frequent forms of cell 
death following irradiation; it occurs after a premature, faulty 
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entrance into mitosis and is characterized as an aberrant nuclear 
morphology, often resulting in the generation of aneuploid 
and polyploid cell progeny that almost always die (1, 3, 17). It 
utilizes anti-proliferative actions, such as apoptosis, necrosis, and 
senescence in order to stop proliferation of mitotic defective cells. 
However, as it is functioning as an onco-suppressive mechanism, 
its failure can also promote unrestricted growth of mitotic defec-
tive cells, making it a major possible contributor to tumor devel-
opment (18). There are two proposed mechanisms for induction 
of MC: its occurrence as a consequence of DNA damage and 
deficient cell cycle checkpoints, and a hyper amplification of 
centrosomes. As most tumor cells have compromised cell cycle 
checkpoints, e.g., as a frequent consequence from mutated or 
inactivated p53, alongside altered apoptotic signaling pathways, 
radiation-induced DNA damage often leads to the induction 
of MC (1, 17).
Radiation-induced Senescence
Reproductive senescence is defined as a condition of permanent 
cell cycle arrest after cells have reached their proliferative capac-
ity. In vitro, cells take on an enlarged and flattened morphology, 
increased granularity and a vacuole-riche cytoplasm. However, 
senescent cells are still viable and metabolically active. Today, 
there are a number of biomarkers typically associated with 
senescence, some of which can easily be detected via histo-
chemical staining procedures (1, 19). Following RT, replicative 
senescence is typically observable as a permanent DNA dam-
age response. While replicative senescence is usually initiated 
when telomeres become critically short and/or the telomere 
cap is compromised, with both ultimately resulting in exposed 
chromosome ends, this state can also occur in the case of DNA 
double-strand breaks (19).
Radiation-induced Autophagy
Autophagy is another form of cellular stress response as well as a 
regulatory way to handle damaged or aged organelles in the cell. 
Whereas there are different forms of it (such as macro-autophagy, 
micro-autophagy, and chaperone-mediated autophagy), in gen-
eral, damaged organelles are enclosed within double membrane 
vesicles (autophagosomes) that consequently fuse with lysosomes 
and are ultimately digested from the lysosomal proteases (20). 
Thus, autophagy usually acts in a pro-survival manner that helps 
to sustain cellular homeostasis and genomic integrity. Within 
tumors, the rate of autophagy is often upregulated in comparison 
to healthy tissues (21). Tumor cell autophagy is thought to have 
different and contrasting functions. One of it is a cytoprotective 
one, possibly serving as a protective measure to protect the tumor 
against therapy-induced apoptosis (21, 22). The other one is a 
rather cytotoxic function that might function to promote tumor 
cell killing, but is rarely observed in conventional treatments 
(22). While, theoretically, both forms of autophagy in tumor 
cells might be subject to alterations in order to further enhance 
the effectiveness of treatment modalities, the role of autophagy 
in cancer is still controversial and is thus, subject to extensive 
research (21, 22): even though it has already become obvious 
that DNA damage responses, inflammation and autophagy are 
inter-connected (23, 24) and it seems that RT almost uniformly 
promotes autophagy in tumor cells, it is currently unsure whether 
RT-induced autophagy should be promoted or inhibited for a 
more beneficial outcome (25).
Non-Targeted effects of Radiation
However, next to these primary effects of RT, one can also 
observe secondary effects following radiation (26): the activa-
tion of the immune system via the induction of immunogenic 
cell death (ICD) by RT (27) (Figure 1). Besides the main target, 
the induction of DNA damage, ionizing radiation is also able to 
modify tumor phenotypes as well as the tumor microenviron-
ment. These, the so-called non-targeted effects, can contribute 
to anti-tumor responses in a specific and systemic manner and 
possess the ability to target relapsing tumor cells as well as distant 
metastases (28). In order to enhance RT-induced anti-tumor 
immunity, additive chemotherapy (CT) and immunotherapy 
(IT) have proven to be useful tools. However, there are still many 
open questions and various hypotheses regarding the effects of 
different concepts of RT on immune activation. One of them, the 
question if today’s RT schemes have heterogeneous influences 
on the immune system, and if certain fractionation schemes and 
doses could be advantageous over others, will be discussed here.
HiSTORY OF RADiOTHeRAPY
In order to better understand some of today’s treatment pros-
pects, a short summary on the rather rapid development of 
clinical RT is helpful. We, therefore, will focus on the history of 
RT within the next paragraph: just a few weeks after Wilhelm C. 
Röntgen discovered X-rays in 1895, Grubbé treated an advanced 
ulcerated breast cancer in Chicago in 1896 using X-rays (29). 
Complications and negative side effects of early X-ray applica-
tions were discovered quickly and taken into account (30). 
In  that matter, Thor Stenbeck used smaller doses of radiation 
over a longer period of time to treat skin cancer in Stockholm 
(31). In 1906, Bergonié and Tribondeau were experimenting with 
X-rays and rat testicles in order to investigate selective influences 
of X-rays on healthy tissues. They discovered that X-rays are most 
effective on cells having (a) a high proliferative rate, (b) a long 
life-span with many divisions, and are (c) unspecialized (32). 
Within the first 40 years after Röntgen’s discovery, RT became 
a routinely used clinical application for both malignant and 
inflammatory diseases. In the 1920s, animal sterilization experi-
ments in rams, carried out by Regaud, showed the advantages of 
splitting the administered radiation into smaller daily fractions: 
this way sterilization of the ram testes was able to be carried out 
with minimal necrosis to the scrotum (33). In 1934, Coutard 
published a paper on principals of X-ray therapy on malignant 
diseases where he showed an impact of treatment time and dose 
on both, the cancer and the surrounding tissues (34). This can be 
seen as the founding of the time–dose factor concept. As a result 
of these and other radiobiological experiments, a consensus on 
a fractionated treatment scheme was found (31). While Coutard 
shed light on time–dose dependencies, Baclesse helped to gain 
insight on dose–volume relationships (31, 35). In the 1960s, 
Ellis and colleagues investigated biological effects with regard 
to dose–time fractionated factors (31, 36).
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Over time, further developments lead to more and more 
precise linear accelerators that paved the way for today’s 
advanced treatment strategies allowing the administration of 
higher tumor doses while sparing healthy tissues. Specialized 
irradiation devices, multi leaf collimators, treatment planning 
software, and new treatment methods, such as intensity modula-
tion and dynamic beam shaping, allow a high-precision tumor 
irradiation. However, a great part of today’s radiation schemes are 
still based on the data that were collected in the very beginnings 
of clinical RT.
ADvANCeMeNTS AND STATe-OF-THe-
ART RADiOTHeRAPY
Considerations About Radiotherapy
Despite modern developments in RT, treatments always affect 
surrounding healthy tissue, at least to a certain degree. Thus, it is 
important to be aware of general side effects and to define organs 
at risk (OARs). However, modern clinical advances provide 
new opportunities, enhancing the anti-tumor effect of RT, while 
simultaneously lowering the damage of adjacent cells and thereby 
reducing possible negative side effects (5). The most common 
state-of-the-art RT options will be introduced in the following.
Conformal Radiotherapy
In the past, 2D open-field irradiation was applied without taking 
a sparing of healthy tissue and especially possible OARs into 
account. Today, however, all radiation therapy treatments are 
prepared with a 3D treatment planning system and are performed 
with the help of a treatment device, which is combined with a 
reproducible positioning system and, thus, allows the shaping 
of irradiation beams around the tumor volume. In this way, the 
tumor region can be irradiated, while healthy tissue can be spared.
intensity Modulation Radiotherapy
Intensity-modulated radiotherapy (IMRT) planning is carried 
out opposed to the planning order in conformal radiotherapy. 
Meaning that all beam dose distributions are derived from the 
target dose distribution (37). This is done via multi leaf collima-
tors that allow applying a very high dose on the tumor, while 
decreasing irradiation of healthy tissue to a minimum. The beam 
intensity is modified heterogeneously for each irradiation field. 
In that way, different doses can be given across the tumor, while 
U-shaped dose distributions allow avoiding OARs, which in turn 
considerably reduces the risk of long-term side effects.
volumetric Modulated Arc Therapy
The volumetric modulated arc therapy (VMAT) aims for beam 
intensity distribution by changing multi leaf collimators configu-
rations and an additional dose rate variation. During treatment, 
the gantry turns for a maximum of one single rotation (38). That 
way, irradiation times can be reduced (39) to 1.5–3  min for a 
200 cGy fraction (38).
image-Guided Radiotherapy
With image-guided radiotherapy (IGRT) the precision of 
irradiation can be further increased. IGRT involves both the 
reduction of positioning errors during treatment, and precise 
segmentation and evaluation of the clinical tumor volume (40). 
In order to achieve this, additional scans can be made to evaluate 
size, localization, and shape of the tumor that can be checked 
against the digital reconstructed radiographs of the planning CT. 
This can be done either before or during the entire RT proce-
dure, with the latter constituting for a more elaborate process. 
Thus, this technique promotes a very precise tumor targeting 
and consequently a better local control and enhanced chances 
of recovery, while the risk of unwanted side effects is reduced. 
A special type of IGRT is the four-dimensional, adaptive RT, 
whereby the fourth dimension is time. The advantage of this 
method is the adjustment of position changes during treatment, 
which is, e.g., necessary in lung cancer where the tumor moves 
by regular breathing.
Stereotactic Body Radiotherapy and 
Radiosurgery
All these advancements paved the way for more and more precise 
RT set-ups that also allow the administration of a single, high, 
very accurately targeted irradiation dose (stereotactic radiosur-
gery) or fractions of larger doses (stereotactic RT). Both allow 
for a very precise radiation strategy by using image-guided and 
computer-assisted systems. Currently, radiosurgery is used for 
some types of brain cancer and in clinical trials for other enti-
ties, such as prostate cancer. Irradiation is applied from several 
positions around the body, resulting in high irradiation doses 
delivered on the tumor while spreading only relatively low doses 
on surrounding, healthy tissue, thus, further reducing the risk 
of possible side effects. This technique is especially relevant for 
brain cancer as well as for tumors that are clearly distinct from 
the surrounding tissue in prostate, lung, spine, liver, pancreas, or 
kidney (41).
Radiation Dose Application
In general, fractionation schemes are based on year long experi-
ence as well as on positive therapy outcome and, thus, can vary 
greatly. While a high number of patients receive classical or con-
ventional RT with 1.8–2.0 Gy per fraction, choosing alternative 
fractionation protocols can be advantageous in order to achieve 
a better tumor control with fewer toxicities (42). Today, there are 
many RT strategies and the total dose can be administered either 
in the form of a few high doses, or in smaller fractions over a 
longer period of time depending on tumor entity, placement, 
and therapeutic goals. Generally spoken, fractionation has the 
advantage of helping the surrounding, healthy, slower proliferat-
ing tissue to recover, while fast proliferating tumor cells can accu-
mulate a greater amount of DNA damage in various, more or less 
radiosensitive, phases of the cell cycle. However, fractionation 
protocols also have diverse effects on the tumor, the surrounding 
tissue, and thus on the immune system.
In most cases, RT is administered in the form of conven-
tional fractionation where multiple fractions of 1.8–2.0  Gy/
day are administered five times a week over 3–7  weeks (4). 
In  a hyperfractionated therapy setting, conventional doses are 
brought down into smaller doses without a change in the overall 
treatment duration. This way the therapeutic potential between 
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late responding normal tissue and tumor tissue is increased 
(43). Typically, patients receive 0.5–2.0  Gy/fraction with two 
fractions/day and two to five times a week, over a time period 
of 2–4 weeks. Patients treated with a hypofractionated scheme 
receive doses of 3–20 Gy/fraction with one fraction/day resulting 
in a reduced therapy time. However, there are also other forms of 
fractionation protocols, for example accelerated protocols: here, 
tumor growth during the treatment is minimized because of a 
shortened overall treatment duration while still using conven-
tional doses (43). Another variant is the so-called accelerated 
hyperfractionation (1.0–1.6 Gy/fraction in five and more frac-
tions/week). However, the limitations in this protocol are mainly 
due to acute toxicities, as both strategies independently increase 
acute reactions (43). In the case of SABR, small lesions, mainly 
in the brain, are treated with higher doses in fewer fractions 
resulting in a promising therapeutic outcome. Fractions and 
doses used for SABR usually are within a 8–30 Gy window and 
consist of 1–5 fractions (44).
In most fractionation schemes, the set values differ greatly, 
depending on the treated cancer entity but also on the clinic or 
treatment facility. However, from a biological point of view, these 
deviations might influence the immune system and tumor cell 
responses differently and lead to a diversified treatment outcome.
CHALLeNGeS OF CURReNT 
RADiOBiOLOGiCAL ReSeARCH
Even though there is extensive research carried out in the field 
of radiation oncology, most of the clinical studies only consider 
effects of radiation on the local tumor tissue. The influence of 
dose fractionation and timing particularly with regard to immune 
activation is not satisfactorily investigated so far. However, this 
is of particular interest, since recent studies, including additive 
immune therapy approaches, showed that not every therapy com-
bination of classical RT concepts and IT is equally successful (45).
Another compounding issue is the comparability of pre-
clinical models with patient treatment: as the transmission of 
ex vivo and in vivo studies onto clinical trials and the outcome 
in patients is already a widely discussed subject, it is even more 
important that experiments are set-up in a way that follows clini-
cal radiation schemes. However, in some cases that also means 
that doses and numbers of fractions need to be adjusted in order 
to retain the biological effective dose. This is also a reason for 
complications in transferability of models as single doses in mice 
might differ in their effect on the experimental tumor from those 
in humans. Furthermore, not all studies even meet these criteria, 
and dose and fraction sizes are often chosen to specifically meet 
the needs of the used model, or according to the possibilities 
of the facility carrying out the experiments, thus, resulting in a 
hampered comparability. Therefore, the rationale for the chosen 
dose and fractionation should be included in every publication 
with pre-clinical model systems.
Biologically effective Dose
The biologically effective dose (BED) is used for isoeffective 
dose calculations. It is defined as a measure to determine the 
biological dose delivered via a combination of dose per fraction 
and a total dose to the precise tissue that can be characterized by 
its α/β ratio. Treatment doses differ in administration, dose per 
fraction and total dose of the irradiation. Conversion follows the 
linear-quadratic model, first described by Douglas and Fowler 
(46), which characterizes the cell survival curve of both tumor 
and healthy tissue. Thus, the BED can be used as an approximate 
measure to adjust fraction size for a wide range of dose fractions 
(47) and to quantify treatment expectations (48). In order for a 
more practical approach for the clinic, the BED can be converted 
into the biological equivalent dose that is calculated in 2 Gy per 
fraction (EQD2). To better compare doses used in pre-clinical 
and clinical settings, information on the BED or EQD2 should 
be mandatory (47).
iNFLUeNCe OF DiSTiNCT RT CONCePTS 
ON iMMUNe ACTivATiON
The establishment of solid tumor tissue presumes that the tumor 
cells have successfully evaded immunosurveillance and are still 
able to do so for longer periods of time. Usually, tumor cells can be 
eliminated by the immune system through a collaboration of the 
innate and adaptive immune system that effectively detects and 
destroys tumor cells. It is, however, possible that single cells are 
not eliminated during the process; those cells can progress into 
an equilibrium phase: in this state the immune system is still able 
to keep the transformed cells under control. However, in the final 
stage of tumor escape, one of the hallmarks of cancer, the dormant 
tumor cells outgrow the surveillance of the immune system due 
to their reduced immunogenicity, establish a immunosuppressive 
microenvironment, and begin to grow progressively (49). Even 
though this involvement of the immune system has been known 
for a long time, it was generally believed that there are no direct 
synergies in between RT-induced local tumor responses and the 
immune system. This is due to the immunosuppressive proper-
ties of RT, as lymphocytes are known to be radiosensitive and 
their levels in the peripheral blood are lowered after RT (50). The 
same effect can be observed in the bone marrow, where RT has a 
damaging effect on monocyte and granulocyte precursors, as well 
as on natural killer cells (51).
Nevertheless, there are emerging hints that the immune system 
can also be stimulated by RT (52) and today it is accepted that, next 
to radiation-induced cell death and growth inhibition, radiation 
can also activate the immune system (52–54). These systemic and 
immune-mediated effects of RT have been described as abscopal 
effects of RT (55, 56).
Currently, the influences of present RT concepts on the 
immune system are still only fragmentarily understood and it 
would be beneficial to gain a better insight about the effects of 
week-long RT on a molecular, cellular, and tissue level (4) as well 
as its effects on immune cells (53). While classical radiobiology 
has created a general understanding about survival curves based 
on varying radiation doses and treatment volumes, and extensive 
research concerning DNA damage and repair capacities following 
RT has been carried out, there is still a lack of data in pre-clinical 
and clinical studies with regard to radiation and its effects on the 
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immune system (51, 57, 58). Consequently, data about the impact 
of RT concepts on immunological consequences are scarce and 
not conclusive (57), and present knowledge will be reviewed in 
the following.
Radiosensitivity of immune Cells
In general, lymphocytes are among the most radiosensitive cells 
within the body (50, 59). Next to the induction of cell death (50), 
the underlying mechanisms of the immune-suppressive effect of 
RT are thought to be the inhibition of the antigen-expressing 
function as well as the downregulation of co-stimulatory 
molecules, such as CD80 and CD86 on immature DCs (60). 
Furthermore, an altered cytokine profile, and RT-induced pro-
liferation stop of their progenitor cells contribute to it (59). On 
the other hand, RT is also able to stimulate the expression of 
immunomodulatory molecules such as co-stimulatory molecules 
in antigen-presenting cells (APCs), T cells, and stromal cells (61) 
as well as to modify the function of DCs in a way that constrains 
endogenous antigen presentation while increasing their cross-
presentation abilities (62).
However, while lymphocyte radiosensitivity is well known, 
the effects of distinct RT doses or administrations on immune 
modulation and on different immune cell subsets are still not 
fully understood (63). Falcke et al. are currently investigating the 
effects of ionizing radiation on different immune cells subsets, 
with special regard to their individual radiosensitivity. They 
found that T cells, B cells, and natural killer cells are among the 
most radiosensitive immune cells, while monocytes are much less 
sensitive (64). Kaina and colleagues revealed that macrophages 
are even more radioresistant than monocytes (65) with doses of 
ionizing radiation up to 2 Gy having no impact on viability and 
functionality of activated macrophages (66).
Merrick et  al. performed experiments with regard to the 
radiosensitivity of DCs. They found that DCs were more resistant 
against radiation-induced (up to 30 Gy) apoptosis than expected, 
with only small changes in their surface phenotype alongside 
with their endocytic, phagocytic, and migratory abilities (67). 
However, irradiated DCs had reduced effectiveness in mixed lym-
phocyte reaction experiments compared to non-irradiated ones. 
Furthermore, matured DCs produced less interleukin (IL)-12 
than the controls while IL-10 levels remained stable. They, thus, 
hypothesize that IR has an effect on DC function possibly leading 
to a shift in the DC-mediated balance between T-cell activation 
and toleration.
With regard to T cells, ablative RT increases T cell priming in 
lymphoid tissues, possibly contributing to the extermination of 
the primary tumor as well as distant metastases in a CD8+ T cell-
dependent manner (63). It has also been shown that high doses 
of ablative RT given in as less as one to three fractions are able 
to generate adaptive immune responses that result in a regression 
of the tumor (68). In the case of myeloid cells, RT can also 
have various effects, as summarized in Ref. (69). In most cases, 
RT-associated recruitment of myeloid-derived suppressor cells 
(MDSCs) and M2 tumor-associated macrophages has a negative 
effect by mediating immune evasion and tumor growth (69). 
In some cases, however, this effect can be reversed. In that matter, 
Deng et  al. (68) showed that a combined RT and  anti-PD-L1 
therapy is able to reduce the numbers of MDSCs and, thus, their 
suppressive effects on the immune system.
These and other examples show that, next to the immuno-
suppressive properties of RT on immune cells, radiation can 
also cause a reduced tumor growth outside the irradiated field. 
This effect is an immune-mediated effect that is observable after 
the administration of various radiation doses and fractiona-
tion schemes, but mostly only in combination with additional 
immune stimulation (58). Furthermore, more knowledge should 
be gained on the genetic landscape of primary vs. metastatic 
and recurrent tumors as it has just recently been performed by 
whole-exome sequencing of head and neck squamous cell carci-
noma (HNSCC) (70). Also, tumors with high somatic mutation 
prevalence do respond better to immunotherapies (71). RCT in 
multimodal settings might generate more neo-antigens that are 
the origin for initiating anti-tumor immune responses. Coupling 
radio-immunotherapies with agents that impact on DNA repair 
pathways might be particularly constructive in this respect (72). 
It is important to stress that more clinical trials are needed to 
more clearly delineate the best combination of RT with IT and/
or DNA repair pathway inhibition and, as outlined above, that 
the optimal approach may differ based on the tumor site and/or 
genetic signature.
Taken all this information into account, it is not exaggerated 
to formulate that the immune system plays a vital role in the fight 
against cancer and that there is a lack of pre-clinical and clini-
cal trials focusing in particular on the role and functionality of 
immune cells after RT.
RADiATiON AND iMMUNOGeNiC 
TUMOR CeLL DeATH
Ionizing radiation can render the tumor microenvironment 
more immunogenic. Following RT, stressed and dying cancer 
cells release a variety of substances, including reactive oxygen 
as well as nitrogen species alongside with cytokines, such as 
IL-6, -8, and tumor necrosis factor-α (TNF-α) that are all able 
to stimulate the immune system and to promote local bystander 
effects. RT-induced apoptosis is characterized by the exposure 
of ER-derived proteins, such as calreticulin and by the release 
of DAMPs. This leads to the recruitment of APCs and, thus, 
the adaptive immune system resulting in a distant out of field 
or abscopal effect. This form of apoptosis is also known as ICD 
(73). Necrotic cells also release the so-called danger signals, such 
as Hsp70 or HMGB1. These bind to receptors, e.g., to toll-like 
receptors (TLRs) on APCs such as DCs, induce their matura-
tion and promote cross-presentation of tumor antigens (53, 74). 
Another inflammatory molecule associated with immunogenic 
cancer cell death is adenosine triphosphate (ATP). By binding 
to receptors on DCs, ATP can stimulate the release of IL-1β 
that in turn can promote T cell priming (74). However, in many 
cases tumor cells do not directly die after treatment. But also, in 
this case, sole exposure of calreticulin might render the tumor 
more sensitive to killing by cytotoxic T lymphocytes (75, 76). 
An additional effect of ionizing radiation is the normalization 
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of tumor vasculature that can also inhibit tumor growth (73), 
moreover, these effects go beyond direct nuclear damage (77). 
As with many of the described effects, radiation-induced changes 
in tumor vasculature are also highly dependent on the applied 
doses and radiation schemes (78). However, even though there is 
a good understanding of these effects, surprisingly little is known 
about how ionizing radiation and RT-connected responses of the 
immune system alter the tumor microenvironment (68, 77) with 
special regard to the impact of different radiation regiments.
impact of Distinct Radiation Doses and 
Fractionation Schemes on Tumor Cell’s 
immunogenicity
Rubner et al. showed in an in vitro model system that fractionated 
RT given at 5 × 2 Gy is the main stimulus for the induction of 
an ICD in glioblastoma cell lines (79). Furthermore, fractionated 
radiation with 2 Gy as single dose induced the release of Hsp70 in 
p53 mutated and O6-methylguanine methyltransferase negative 
glioblastoma cell lines. As the danger signal Hsp70 is able to 
activate DCs, classical fractionation might be beneficial to create 
a favorable tumor microenvironment for the integration of IT. 
An experimental study carried out by Kulzer et  al. dealt with 
the capability of the colorectal tumor cell line SW480 to activate 
DCs after the application of various RT schemes (80). Immature 
DCs cultivated with supernatants from tumor cells treated with 
either classical (5 ×  2  Gy) or hypofractionated (3 ×  5  Gy) RT 
secreted significantly elevated levels of the immune activating 
cytokines IL-12p70, IL-8, IL-6, and TNF-α compared to imma-
ture DCs stimulated with supernatants of SW480 cells treated 
with 1 × 15 Gy. Furthermore, only supernatants of fractionated 
irradiated cells resulted in elevated DC-maturation markers 
after immature DC co-cultivation and merely those were able 
to stimulate CD4+ T cells in an antigen-specific matter. Tsai 
et  al. investigated gene expressions in the breast, prostate, and 
glioma cell lines MCF-7, DU145, and SF539 after RT with either 
1 ×  10  Gy or 5 ×  2  Gy (81). They found differences in gene 
expression patterns depending on radiation protocols. In that 
matter, a fractionated radiation resulted in a more robust gene 
induction than that of single doses. In addition, they also found 
a small subset of interferon (IFN)-related identical genes, a group 
of genes that has been implicated in inflammation, upregulated 
in all three tumor cell lines following fractionated irradiation. 
Deng et al. showed that in DCs the adaptor protein STING was 
required for IFN-γ induction in response to irradiated-tumor 
cells (82). Here, a high single ablative dose of 20  Gy was used 
for the experiments.
Taken together, these selected in  vitro results propose (1) 
the ability of ionizing radiation to induce immunogenic effects 
and (2) a superior outcome of fractionation schemes over single 
high doses of radiation (Figure 2). However, these ex vivo assay 
systems only give hints about the immunogenic potential of the 
tumor cells and pre-clinical in vivo experiments and clinical stud-
ies are ultimately needed (83).
Pre-clinical mouse models often suggest a more beneficial 
outcome if higher doses are used in hypofractionated schemes 
(84, 85). Multhoff et  al., thus, support the assumption that 
long-lasting, daily repeating RT leads to lymphocyte death (53) 
and longer breaks during the radiation are needed to give the 
immune system time to act and re-act (86). Dewan et al. report 
that fractionated, but not single doses induce immune-mediated 
abscopal effects in combination with a CTLA-4 antibody (84). 
While a single high dose (1 × 20 Gy) and fractionation regiments 
both had the ability to control primary tumor growth in a TSA 
breast cancer and MCA38 colon cancer mouse model, no effects 
on a distant secondary tumor could be found after ablative RT. 
However, they also found that 3 × 8 Gy was superior to lower 
doses of RT that have been applied more often (5  ×  6  Gy), 
suggesting advantageous effects of hypofractionated schemes. 
Schaue et al. carried out experiments in mice bearing B16-OVA 
melanoma. They found that single doses of radiation from 7.5 
to 15  Gy had a dose-dependent impact on tumor control, and 
tumor-reactive T cells, with an offset at 15  Gy. However, after 
15 Gy they also found increasing numbers of Tregs. A single dose 
of 5 Gy had only little impact on tumor control. However, a frac-
tionated treatment scheme with medium-sized doses of 7.5 Gy/
fraction resulted in the best tumor control and immunity with 
low Treg numbers (85). By contrast, Lee et al. observed a CD8+ 
T cell-dependent immunity and tumor reduction, together with a 
reduced relapse of the primary tumor, as well as an eradication of 
metastases in some cases particular after high dose or ablative RT 
with 1 × 15–25 Gy in various cancer models. They also show that 
these ablative RT-mediated effects are abrogated by conventional 
fractionated RT or adjuvant CT while locally administered IT 
enhances the effects (63). Thus, they imply a limitation rather 
than a stimulation of RT-mediated tumor immunity caused by 
some of the currently used RT/CT strategies. Lugade et al. evalu-
ated anti-tumor immune responses after single dose (1 × 15 Gy 
on day 7) or fractionated (5 × 3 Gy on days 7–11) RT in mice 
injected with OVA-expressing B16-F0 tumors (61). With regard 
to long-term tumor control, neither of the two RT schemes was 
able to effectively prevent tumor growth. Non-irradiated mice 
showed large tumors by day 14 and single dose treatment was 
rather effective during the initial time period of 14 days. However, 
at day 30, the mice that had received a single dose of 15 Gy also 
had to be sacrificed due to a large tumor burden. Surprisingly, 
the 5 ×  3  Gy fractionated scheme showed only slightly better 
tumor growth control rates than non-irradiated controls. With 
regard to APC activity, the single high-dose treatment resulted 
in a threefold increase in APC activity, while mice treated with 
fractionated RT showed APC activity to a lesser extent. Using 
immunohistochemistry and flow cytometry analyses, numbers of 
total immune cells (defined by CD45 expression) and immune 
cell subtypes infiltrating the tumor were also analyzed. In general, 
irradiation resulted in higher numbers of total CD54+ cells and 
for all of the subsets than in non-irradiated tumors. With regard 
to RT schemes, in mice that received the single high dose the 
average number of infiltrating immune cells per tumor mass was 
higher than in those receiving the fractionated scheme. These 
results suggest that single high doses represent a more beneficial 
treatment plan, at least in this model. Shi et al. investigated the 
effects of an anti-CD137 antibody in combination with differ-
ent fractionation schemes in murine lung (M109) and breast 
(EMT6) carcinoma models (87). CD137 is a member of the 
FiGURe 2 | influence of RT schemes on the tumor cells immunogenicity in selected in vitro and in vivo model systems. Gy, Gray; ICD, immunogenic cell 
death; Hsp70, heat shock protein 70; DC, dendritic cell; SN, supernatant; APC, antigen-presenting cell; Treg, regulatory T cell; IFNγ, interferon γ; CTLA-4, cytotoxic 
T lymphocyte-associated protein 4; AB, antibody.
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TNF-receptor superfamily and is able to deliver a co-stimulatory 
signal for T cell activation. Administration of the antibody in 
combination with a single dose RT (5, 10, or 15  Gy) resulted 
in an enhanced anti-tumor effect in the case of EMT6 tumors. 
Regarding M109 tumors, only the highest dose of 15 Gy resulted 
in enhanced tumor response rates. These results once more show 
that an individual evaluation of tumor entity and chosen RT 
treatment plan are crucial for an optimized outcome. Witham 
et  al. examined if radiosurgery also induces apoptosis next to 
necrosis in an experimental rat glioma model (88). They aimed 
to investigate whether radiosurgery (a) induces tumor apoptosis 
and if this correlates with a survival benefit and (b) whether 
the extend of apoptosis and its time course provides a basis for 
other treatment modalities, such as IT. They treated Fischer 
344 rats with established intercranial 9L gliosarcomas with 
radiosurgery (max. dose 70  Gy) and sacrificed the animals at 
3, 6, 12, 24, 48, 72  h, and 1, or 2  weeks after treatment. They 
revealed that tumor apoptosis was significantly higher at the 6-, 
24-, and 48-h time point in comparison to untreated controls. 
They, thus, hypothesize that radiosurgery induces apoptosis in 
a time-dependent manner, possibly giving the opportunity to 
combine radiosurgery with IT, that utilizes tumor apoptosis for 
antigen presentation. Park et al. investigated the influence of the 
expression of the immune checkpoint molecule PD-1 on the 
systemic anti-tumor response induced by SABR in pre-clinical 
melanoma and renal cell carcinoma models (89). They found 
that the observed abscopal effect was tumor specific and that in 
particular a combination of SABR with PD-1 blockade was able 
to induce it. Selected examples of the influence of RT regiments 
on immune stimulation are summarized in Table 1.
TABLe 1 | The influence of fractionation regiments on immune stimulation in selected pre-clinical in vitro and in vivo models.
experiment 
type
Tumor entity Tumor model Fractionation 
regiment
Additional  
therapy
Observed immune modulations Source
In vitro Glioblastoma U87MG, T98G, 
U251
5 × 2 Gy ±TMZ and VPA Hsp70 and HMGB1 secretion ↑ in irradiated tumor 
cell lines
(79)
In vitro Colorectal 
carcinoma
SW480 5 × 2 Gy, 3 × 5 Gy, 
1 × 15 Gy
– 5 × 2 Gy and 3 × 5 Gy: IL-12p70, IL-6, IL-8, and 
TNF-α secretion↑, DC-maturation markers↑, CD4+ 
T cell stimulation with SN treated iDCs
(80)
In vitro Breast, prostate, 
glioma
MCF-7, DU145, 
SF539
5 × 2 Gy, 1 × 10 Gy – 5 × 2 Gy: more robust gene induction, upregulation of 
IFN-related genes
(82)
In vitro Breast cancer MCF-7, 
MDA-MB231
4 × 4 Gy, 6 × 3 Gy, 
1 × 4/10/20 Gy
HT, ± zVAD-fmk Clonogenicity MCF-7↓↓, MDA-B231↓
Hypofractionation is main stimulus for cell death 
induction and DC activation in MDA-MB231 cells
(90)
In vitro Prostate cancer LNCaP, PC3, 
DU145
10 × 1 Gy, 
1 × 10 Gy
– 10 × 1 Gy: more robust immune response gene 
induction, number of induced immune genes PC3↑↑, 
DU145↑, LNCaP↑
(91)
Induction of pro-inflammatory DAMPs and cytokine 
modulation (10 × 1 Gy ↑↑, 1 × 10 Gy ↑)
In vitro Breast cancer TSA 1 × 2/5/10/20 Gy Carboplatin, 
oxaliplatin
Dose-dependent induction of ICD
Chemotherapeutic enhancement of ICD
(92)
In vitro C57BL/6J, 
Tmem173−/−, 
and Irf3−/− mice
BMDCs 1 × 20 Gy – STING is required for the anti-tumor effect of radiation 
and type I IFN induction
(82)
In vitro Melanoma MeIJuSo 1 × 1/4/10/25 Gy – RT modulates peptide repertoire and enhances MHC 
class I expression in a dose-dependent manner
(93)
In vitro Colorectal 
carcinoma
HCT116, 
SW620
1 × 10 Gy – HCT116: OX40↑, 41BB↑ ligands
Induction of genes associated with T cell effector 
activities
(94)
In vivo Breast carcinoma TSA, MCA38 5 × 6 Gy, 3 × 8 Gy, 
1 × 20 Gy
9H10 Growth reduction of secondary, out-of-field tumors 
(5 × 6 Gy + 9H10↑, 3 × 8 Gy + 9H10↑↑)
(84)
In vivo Melanoma B16-OVA 1 × 5/7.5/10/15 Gy – Dose-dependent increased tumor control (5 Gy↓) and 
tumor-reactive T cells (15 Gy↓), 15 Gy Tregs↑, 7.5 Gy 
superior tumor control and low Treg numbers
(85)
In vivo Mammary and 
lung carcinoma, 
melanoma
4T1, B16, B16-
SIY, B16-CCR7, 
A549
1 × 15–25 Gy CD8+ T cell-dependent immunity↑, tumor reduction↑, 
abrogation of observed effects after conventional 
fractionated RT or CT, IT enhances the observed 
effects
(63)
In vivo Melanoma OVA expressing 
B16-F0
5 × 3 Gy, 1 × 15 Gy – No significant effects on tumor growth, APC activity, 
total immune cells, tumor infiltrating immune cell 
subtypes: 5 × 3 Gy↑, 1 × 15 Gy↑↑
(61)
In vivo Lung and breast 
carcinoma
M109, EMT6 1 × 5/10/15 Gy Anti-CD137 
antibody
EMT06: all doses ↑ anti-tumor effect
M109: 15 Gy ↑ anti-tumor effect
(87)
In vivo Rat glioma 70 Gy max dose – Tumor apoptosis↑ after RT in a time-dependent 
manner
(88)
In vivo Breast cancer TSA 3 × 8 Gy Imiquimod, 
cyclophosphamide
Combination of imiquimod, RT, and cyclophosphamide 
induces protective immunologic memory, tumor 
infiltration by CD11c+↑, CD4+↑, CD8+↑ cells
(95)
In vivo Colon cancer CT26, MC38 1 × 30 Gy – Transformation of immunosuppressive tumor 
microenvironment, CD8+↑ tumor infiltrates, MDSCs↓
(96)
In vivo Sarcoma MethA, C3 3–5 × 10 Gy DC administration Anti-tumor response↑ (97)
In vivo Melanoma D5 5 × 8.5 Gy Intratumoral DC 
administration
Local and systemic anti-tumor response↑ (98)
In vivo Lung carcinoma, 
fibrosarcoma
LLC, T241 5 × 10 Gy, 
12 × 2 Gy
– 5 × 10 Gy: out of field tumor growth↓ (99)
12 × 2 Gy: LLC tumor growth↓, implicated dose-
dependent efficiency of abscopal effect, p53 as key 
mediator for the abscopal effect
↑, increase; ↓, decrease; Gy, Gray; TMZ, temozolomide; VPA, valproic acid; Hsp70, heat shock protein70; HMGB1, high mobility group box 1; IL, Interleukin; TNF-α, tumor necrosis 
factor-α; SN, supernatant; DC, dendritic cell; iDC, immature DC; IFN, interferon; BMDC, bone marrow-derived cells; STING, stimulator of IFN genes; HT, hyperthermia; DAMP, 
danger-associated molecular pattern; ICD, immunogenic cell death; Treg, regulatory T cell; RT, radiotherapy; CT, chemotherapy; IT, immunotherapy; MDSC, myeloid-derived 
suppressor cell; APC, antigen-presenting cells.
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CLiNiCAL HiNTS FOR iMMUNOGeNiC RT
While fractionation generally reduces toxicity to the surround-
ing tissue and enhances DNA damage in tumor cells, there 
is also evidence that prolongation of the overall treatment 
time has a negative impact on the outcome of certain tumors 
(100). In that matter, there is a possibility to alter fractiona-
tion protocols in an accelerated manner, however, this is not 
suitable for all cancer entities, as, e.g., OARs might be close by. 
Innovative RT protocols have to consider this as well as to take 
the immunogenic potential of distinct doses and fractionations 
and of the genetic signature of the tumor into consideration. 
Also, there are no consistent radiation schemes throughout 
different centers. However, there are ambitions to come to a 
conclusion regarding detailed recommendations of the treat-
ment process. In that matter, Guckenberger et  al. have given 
a detailed report about guiding principles for the treatment 
of stage I non-small cell lung cancer (NSCLC) (101). Sterzing 
et  al. gave a detailed overview of current SABR treatment in 
the case of liver tumors (102).
Clinical evidence for enhanced  
immunity after RT
Next to pre-clinical evidences that demonstrate how RT can 
modulate the immune system and enhance immunity, there is 
also clinical evidence for this phenomenon. The abscopal effect, as 
already described by Nobler in 1969 (103), defines the regression 
of distant tumors outside of the irradiation field without the help 
of additional therapeutic options. As nowadays we have prove 
that this effect is immune mediated (56, 86), the description 
systemic immune-mediated effects of RT is more appropriate and, 
thus, should be used. Even though there are only few reported 
cases, this effect clearly shows the ability of RT to modulate the 
immune system and cases for various cancer entities have been 
described (104):
In that matter, Konoeda reported an abscopal effect in pre-
operatively irradiated patients, which was verified by palpation 
on metastatic lymph nodes in 15 out of 42 cases (35.7%), and 22 
out of 42 cases (52.4%) through histopathological findings (105). 
He also reports a significantly higher incidence in patients under 
55 years of age (age distribution: 29–84 years; mean 54 years) and 
in those who showed infiltrating lymphocytes allocated around 
the degenerated cancer cells within the irradiated primary 
tumors, further supporting the involvement and stimulation of 
the immune system after RT. Using monoclonal antibodies in 
immunohistological stainings, the infiltrating lymphocytes were 
identified as CD8+ and CD4+ T cells. He, thus, concluded that 
the observed effect was caused by an activated immune system 
in the patients.
Okuma et  al. report a case of a 63-year old man suffering 
from hepatocellular carcinoma. After extended right hepatic 
lobectomy, a single lung metastasis and a single mediastinal 
lymph-node metastasis were found (106). As the first therapy 
option in the form of trans-catheter arterial embolization failed 
to work and carried the risk of spinal artery embolism, the patient 
received RT with a total dose of 60.75 Gy in 2.25 Gy fractions. 
Computed tomography scans showed significant reduction of the 
mediastinal lymph-node metastasis and spontaneous shrinking 
of the lung metastasis that was located outside of the irradiation 
field. No chemotherapy was given during the treatment and 
there has been no recurrence of either of the metastases during a 
10-year follow-up period after RT.
There are in particular hints, that additional IT further 
enhances these effects. Golden et al. conducted a proof-of-prin-
cipal trial (ClinicalTrials.gov, NCT02474186) using granulocyte-
macrophage colony-stimulating factor (GM-CSF) as an effective 
stimulator of DC maturation (107). Forty-one patients with stable 
or progressing metastatic solid tumors who received single-agent 
CT or hormonal therapy were treated with concurrent RT (35 Gy 
total dose; 3.5 Gy/fractions for 2 weeks) to one metastatic site as 
well as daily subcutaneous injections of 125 μg/m2 GM-CSF for 
2  weeks, starting at the second week of RT. This regiment was 
repeated targeting a second metastatic site. They found abscopal 
responses in 11 (26.8%, 95% CI 14.2–42.9) out of 41 patients. 
They, thus, conclude that a combinatory therapy approach with 
RT and GM-CSF is able to produce out-of-field responses in 
patients with metastatic solid tumors.
Grimaldi et al. also suggest a possible synergistic effect of IT 
and RT (108): they examined patients with advanced melanoma 
who were treated with ipilimumab, an immune checkpoint block-
ade monoclonal antagonist, followed by RT. Out of 21 patients, 13 
(62%) received RT to treat metastases in the brain and 8 patients 
directed at extracranial sites, respectively. Thirteen patients (62%) 
showed local responses and among those, systemicl responses 
were observed in 11 patients (52%). Out of those 11 patients, 
9 had partial responses (43%) and 2 had stable disease (10%). 
As distant effects were only observed in patients showing local 
responses, they suggest a connection of local responses to RT with 
distant effects.
Taken together, all these clinical data suggest a vital role of the 
immune system after RT. It would, however, be beneficial to know 
whether certain radiation regiments have a superior effect over 
others in terms of immune stimulation.
impact of Radiation Dose and 
Fractionation on Side effects
Fu et al. investigated the late effects of a phase ILE/II dose escala-
tion trial (RTOG 83-13) for hypofractionated RT (109). In that 
study, 479 patients with advanced head and neck cancer were ran-
domly assigned to receive doses of either 67.2, 72, 76.8, or 81.6 Gy 
delivered at 1.2 Gy/fraction twice a day for 5 days/week. Patients 
were subclassified by the delivered doses and by the average daily 
interfraction interval of ≤4.5 or >4.5 h, respectively. Distribution 
of patients resulted in well-balanced treatment groups and the 
median follow-up was 1.71 years (0.24–9.6) for all patients and 
6.12 years for 85 alive patients. No significant impact in the occur-
rence of late effects was observed; however, the incidence of late 
effects significantly differed with respect to the daily interfraction 
interval. Multivariant analysis showed that a daily interfraction 
interval of ≤4.5 h was the only significant independent prognosis 
for the development of grade 3+ or grade 4 late effects (p = 0.0167 
and p =  0.0013). This study showed no evident dose–response 
relationship for the investigated doses; however, it did stress the 
importance of other factors in RT.
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The RTOG 90-03 study (110, 111) examined three different 
radiation schemes with regard to local-regional tumor control 
(LRC) in comparison to standard fractionation for squamous cell 
cancers (SCC) of the head and neck. For that reason, patients with 
stage III or IV SCC were randomized to the four treatment arms: 
(a) standard fractionation scheme at 70 Gy delivered in 35 daily 
2 Gy fractions over 7 weeks; (b) hyperfractionated protocol with 
a total dose of 81.6 Gy administered at 68 twice-daily 1.2 Gy doses 
for 7  weeks; (c) accelerated fractionation, continuous meaning 
72  Gy in 42 1.8  Gy fractions during 6  weeks; (d) accelerated 
fractionation with split with 67.2 Gy at 42 1.6 Gy fractions within 
6 weeks with a 2-week break after a dose of 38.4 Gy. At the first 
follow-up (111), patients who were treated with hyperfraction-
ated protocol and continuous accelerated fractionation showed 
significant better LRCs (p = 0.045 and p = 0.050, respectively) than 
patients receiving standard fractionation scheme. Accelerated 
fractionation with split patients, on the other hand, showed simi-
lar outcome to those treated with standard fractionation scheme. 
However, all experimental RT schemes had significantly higher 
acute side effects in comparison to the standard fractionation 
protocol. For LRC at 5  years, only hyperfractionated protocol 
was different from standard fractionation scheme (110), hyper-
fractionated protocol improved the overall survival (OAS; hazard 
rate 0.81, p = 0.05). Any other side effects or toxicities did not 
differ significantly from standard fractionation scheme. However, 
in a comparison of 7-week treatments with 6-week treatments, 
accelerated fractionation appeared to increase grade 3, 4, or 
5 toxicity at 5 years (p = 0.06). Even though after 5 years only 
hyperfractionated protocol significantly improved LRC and OAS 
for patients with locally advanced SCC without an increase in 
late toxicity, it was also shown that accelerated fractionation and 
shorter treatment durations enhance toxicity. These results stress 
the importance of long-term follow-ups with regard to judge LRC 
as well as side effects.
impact of Radiation Dose and 
Fractionation on Anti-Tumor effects
As there are several studies comparing the effects of conven-
tional RT and hyperfractionated or accelerated RT in patients 
suffering from HNSCC, with unclear results in regard to OAS, 
Bourhis et  al. carried out a meta-analysis in order to answer 
that question: they acquired data from 15 trials of patients 
suffering from HNSCC and grouped them in three categories: 
hyperfractionated, accelerated, and accelerated with total dose 
reduction, with OAS as the end point (112). Median follow-up 
of the analysis was 6 years and a significant survival benefit with 
altered fractionation protocols was found (absolute benefit of 
3.4% at 5  years with a hazard rate of 0.92, 95% CI 0.86–0.97; 
p = 0.003). Among the fractionation protocols, hyperfraction-
ated RT posed as a significantly better therapeutic option than 
accelerated RT (8 vs. 2% with accelerated fractionation without 
total dose reduction and 1.7% with total dose reduction, respec-
tively). Next to OAS, there was also a visible benefit with regard 
to LRC also in favor of altered fractionation protocols (6.4% 
at 5 years; p < 0.0001). The observed benefit was significantly 
higher in the youngest patients [HR 0.78 (0.65–0.94) for under 
50-year-olds, 0.95 (0.83–1.09) for 51- to 60-year-olds, 0.92 
(0.81–1.06) for 61- to 70-year-olds, and 1.08 (0.89–1.30) for 
over 70-year-olds; p = 0.007].
Norihisa et  al. examined SABR for oligo metastatic lung 
tumors. In their study, they involved a total of 34 patients with 
the following primary involved organs: lung (n = 15), colorectum 
(n = 9), head and neck (n = 5), kidney (n = 3), breast (n = 1), and 
bone (n = 1) (74). They used 6 MV photon beams to deliver 48 Gy 
(n = 18) or 60 Gy (n = 16) with 12 Gy/fraction within 4–18 days 
(median: 12 days). OAS, local relapse-free rate and progression-
free rate at 2 years was 84.3, 90.0, and 34.8%, respectively, with no 
progression observed in tumors irradiated with 60 Gy. Pulmonary 
toxicities were observed in four grade 2 cases (12%) and one 
grade 3 case (3%). As a result, 48 vs. 60 Gy showed no significant 
differences in survival rates, but differed in the local progression 
rate (p = 0.078). Thus, a dose escalation from 48 to 60 Gy resulted 
in an increased LCR without an increase in incidence or severity 
of pulmonary toxicity [13 (72%) and 2 (11%) at 48 Gy and 10 
(63%) and 2 (13%) at 60 Gy, respectively] (74).
Guckenberger et al. carried out a pattern of care analyses in 
stage I NSCLC patients that, among other factors, also examined 
various fractionation schemes. They found that the most com-
monly used fractionation protocols were 3 × 12.5 Gy (prescribed 
to the 60 to 65% isodose line, n = 147) and 3 × 15 Gy (prescribed 
to the 65% isodose line, n = 107). Among all patients within this 
pattern of care study (n = 582) only six received >10 fractions. 
They came to the conclusion that SABR is a safe and effective 
treatment option in stage I NSCLC (113), further they found 
a fractionation scheme using 3  ×  15  Gy to be the preferred 
treatment option that resulted in local tumor control rates of 
>90% (101).
The UK standardization of breast RT (START) trial (interna-
tional standard randomized controlled trial ISRCTN59368779) 
compared a dose of 50  Gy in 25 fractions given over 5  weeks 
with 41.6 or 39 Gy in 13 fractions given over 5 weeks in women 
with completely excised invasive breast cancer (pT1-3a, pN0-1, 
M0) (114). The 5-year results suggested that lower total doses 
of RT that are administered in fewer, larger fractions are at least 
as safe and effective as standard RT schemes in women after 
primary surgery for early breast cancer. The 10-year follow-up 
(median follow-up 9.3  years; IQR 8.0–10.0) confirmed that 
hypofractionation, if given in appropriate doses, can be a safe and 
effective treatment option for patients with early breast cancer. 
The study further supports a 40 Gy in 15-fraction regiment that 
has already been adopted by most UK centers as the standard 
of care for women requiring adjuvant radiotherapy for invasive 
early breast cancer.
Running and future trials will now have to identify whether 
high-dose RT is superior to induce anti-tumor immune responses 
compared to classical fractionated RT or hyperfractionated RT 
and in particular how the outcome is when RT is combined with 
IT. A recent study showed that SABRand IMRT induce different 
plasmatic cytokine changes in NSCLC patients. This supports 
the hypothesis that RT regimes of dose schedules and techniques 
have different impacts on induction of anti-tumor immunity 
(115). Exemplary studies for current knowledge on that subject 
are summarized in Table 2.
TABLe 2 | The impact of fractionation regiments on local and systemic responses in selected clinical studies.
Tumor entity Fractionation regiment Additional therapy Observed effects Source
Out-of field 
responses
Hepatocellular 
carcinoma
60.75 Gy in 2.25 fractions – Shrinkage of out-of-field metastases in the lung and 
lymph node
(106)
Stable or 
progressing 
metastatic solid 
tumors
35 Gy in 3.5 Gy/fraction 
for 2 weeks
Subcutaneous 
GM-CSF + CT/hormonal 
therapy
Out-of-field responses in 11 (26.8%, 95% CI 
14.2–42.9) out of 41 patients
(107)
Advanced 
melanoma
5 × 4 Gy
3 × 10 Gy
25 × 2 Gy
1 × 20/24 Gy
Ipilimumab 3 mg/kg i.v. 
every 3 weeks for four 
doses
Out-of-field responses in 11 (52%) patients (108)
Side effects Advanced head 
and neck cancer
67.2/72/76.8 Gy in two 
1.2 Gy/fractions/day for 
5 days/week
– No evidence for a dose–response relationship
Daily interfraction interval ≤4.5 h as only significant 
prognosis for the development of grade 3+ and 4 late 
effects (p = 0.0167 and p = 0.0013)
(109)
HNSCC;  
stage II or IV
(a) 35 × 2 Gy
(b) 68 × 1.2 Gy
twice a day
(c) 42 × 1.8 Gy
(d) 42 × 1.6 Gy with a 
2-week break at 38.4 Gy
– (b) and (c) ↑ LRC than (a) (p = 0.045; p = 0.050)  
(a) and (d) similar outcome
(b)–(d) ↑ acute side effects than in (a)
(b) ↑ AS in comparison to (a) (HR 0.81; p = 0.05)
Only (b) ↑ LRC significantly without an increase in late 
toxicity
Accelerated fractionation used (c), (d) ↑ grade 3, 4, 5 
toxicity at 5-year follow-up
(110, 111)
Anti-tumor 
effects
HNSCC (a) Hyperfractionated
(b) Accelerated
(c) Accelerated with total 
dose reduction
– Survival benefit with altered fractionation protocols 
(absolute benefit of 3.4% at 5 years, HR 0.92, 95% CI 
0.86-0.97; p = 0.003)
(a) ↑ therapeutic option than (b) and (c)
(a) ↑ LRC in favor of altered fractionation protocols 
(6.4% at 5 years, p < 0.0001)
Younger patients ↑ effects (≤50 years: HR 0.78 
[0.65–0.94]; 51–60 years HR 0.95 [0.83–1.09]; 
61–70 years HR 0.92 [0.81–1.06]: >70 HR 1.08 
[0.89–1.30]; p = 0.007)
(112)
Oligo metastatic 
lung tumors
(a) 48 Gy in 12 Gy 
fractions
(b) 60 Gy in 12 Gy 
fractions
– No difference in survival rates
Dose escalation from 48 to 60 Gy ↑ LCR (p = 0.078)
(74)
Invasive breast 
cancer
(a) 50 Gy in 25 fractions
(b) 41.6/39 Gy in 13 
fractions
- 5- and 10-year follow-up: hypofractionation in 
appropriate doses can be a safe and effective 
treatment option
40 Gy in 15 fractions adopted as standard of care by 
most UK centers
(114)
NSCLC (a) 52 Gy in eight fractions 
(SABR)
(b) 60 Gy in 25 fractions 
(IMRT)
– (a) ↓ of IL-10 and IL-17 plasma levels in between the 
first and last day of treatment
(b) ↓ of IL-1, IL-1ra, IL-2, IL-12, FGF-2, MIP-1α,  
MIP-1β, TGF-α, TNF-α, VEGF plasma levels within the 
first 4 weeks of treatment
(115)
Hepatic 
metastases
(a) 3 × 10 Gy
(b) 5 × 10 Gy
(c) 5 × 12 Gy
– Statistically relevant differences in response rates at 
60 vs. 50 Gy and 60 vs. 30 Gy (p = 0.03; p = 0.001); 
↑ LC in 60 Gy cohort
(116)
Colorectal liver 
metastases
(a) 1 × 18–30 Gy
(b) 3 × 12
(c) 6 × 4
72% ≥ 1 CT regiment
42% ≥ 2 CT regiment 
before SABR
Dose-dependent LC: 18-month LC 84% for total 
doses ≥42 Gy and 43% for total doses <42 Gy
Recommendation for a >90% LC 3-fraction regiment 
is ≥48 Gy
(117)
↑, increase; ↓, decrease; Gy, Gray; GM-CSF, granulocyte-macrophage colony-stimulating factor; i.v., intravenously; HNSCC, head and neck squamous cell carcinoma; LRC, local-
regional tumor control; OAS, overall survival; HR, hazard rate; NSCLC, non-small cell lung cancer; SABR, stereotactic ablative body radiotherapy; IMRT, intensity-modulated radio 
therapy; IL, interleukin; FGF-2, fibroblast growth factor-2; MIP, macrophage inflammatory protein; TGF, transforming growth factor; VEGF, vascular endothelial growth factor; LC, local 
control; CT, chemotherapy.
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OUTLOOK AND SUMMARY
Recent studies led to a paradigm shift that RT can also achieve an 
immunostimulatory effect either by directly influencing immune 
cells or through a modification of the tumor microenvironment 
(53, 68, 73, 74). Consequently, more and more emerging evi-
dence points to the fact that the choice of RT dose and fraction 
plays a crucial role in cancer therapy and current RT concepts 
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might need to be modified in order to achieve the best local 
and systemic therapy outcome (27, 63). Due to the technical 
advancements of today, RT can be administered in a more and 
more precise matter that is opening the door for new treatment 
strategies, such as SABR. The latter seem to have a beneficial 
outcome over classical RT fractionation in pre-clinical animal 
models (63,  84), even though in vitro model systems suggest an 
advantage for classical fractionated RT (79, 80). This discrepancy 
shows that model systems that complement one another are 
needed to get hints about the immunogenic potential of distinct 
radiation doses and fractionation schemes. It further raises the 
question if doses, which are used in the clinic, can be directly 
transferred onto pre-clinical models or if they need adjustments 
based on the BED in order to more closely mimic the processes 
in the patient. Clinical studies also show that there are many 
more factors, such as interfraction intervals (109) or the duration 
of the observation period (110, 111), that need to be taken into 
consideration as it is true for the genetic signature of the indi-
vidual tumor. In order to identify the most immunogenic doses 
and RT protocols, either as a stand-alone therapy option or in 
combination with CT and/or IT, we first need to understand the 
basic mechanisms and conduct appropriate studies (118, 119). It 
is also important to keep in mind that there is significant varia-
tion between patients with regard to RT side effects. This might 
result in the administration of sub-maximal doses as current 
thresholds are set to fit the needs of those who are the most 
sensitive to radiation (120), but that also means that SABR might 
not be the optimal therapy option for all patients. In that matter, 
patients could benefit from a more personalized medicine. Thus, 
in order to achieve an optimized treatment outcome, it seems to 
be necessary to go back from bed to bench side first to be able 
to ultimately bring new insights back to the clinic to deliver the 
best possible therapy to the patients.
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